Media.Player

Neuropeptide treatment for dry eye and dry mouth syndromes

Summary

This technology is a combination of anti-inflammatory neuropeptides for topical treatment of dry eye and dry mouth syndromes.

Technology Benefits

Oxytocin, secretin, and vasopressin are already available individually as drug treatmentsTreatment targets underlying cause of dry eye and dry mouth syndromesCan be locally delivered to the affected areas (eyes or mouth)Can be formulated as either an aqueous solution or an ointmentCan be used in combination with other pharmaceutical agents

Technology Application

Topical treatment of dry eye and dry mouth Treatment for blepharitisTreatment for Sjogren’s syndromeProphylactic treatment of dry eye or dry mouth caused by drug-related side effects or in premenopausal womenCombination therapy with other active pharmaceutical agents for allergy treatmentResearch tool to study the inflammatory pathways in dry eye and dry mouth

Detailed Technology Description

None

*Abstract

None

*Inquiry

Joan MartinezColumbia Technology VenturesTel: (212) 854-8444Email: TechTransfer@columbia.edu

*IR

CU13261

*Principal Investigator

*Publications

Tech Ventures Reference:IR CU13259, IR CU13261Licensing Contact: Joan Martinez

Country/Region

USA